Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas

[1]  W. Qin,et al.  Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma , 2018, Journal of magnetic resonance imaging : JMRI.

[2]  Stephanie M. Rockfield,et al.  Expression and function of nuclear receptor coactivator 4 isoforms in transformed endometriotic and malignant ovarian cells , 2017, Oncotarget.

[3]  Jinbao Liu,et al.  HSP27-Mediated Extracellular and Intracellular Signaling Pathways Synergistically Confer Chemoresistance in Squamous Cell Carcinoma of Tongue , 2017, Clinical Cancer Research.

[4]  Zhuo Xi,et al.  Role of HCP5-miR-139-RUNX1 Feedback Loop in Regulating Malignant Behavior of Glioma Cells. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[6]  Thomas C. Chen,et al.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. , 2015, JAMA.

[7]  Shi-ting Li,et al.  Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma , 2015, Oncotarget.

[8]  Steve Horvath,et al.  Accelerated epigenetic aging in Down syndrome , 2015, Aging cell.

[9]  C. Dardis,et al.  Immunotherapeutic Advancements for Glioblastoma , 2015, Front. Oncol..

[10]  E. Domany,et al.  Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma , 2015, Genome Biology.

[11]  N. Menjot de Champfleur,et al.  Assessment and treatment relevance in elderly glioblastoma patients. , 2014, Neuro-oncology.

[12]  Winston Timp,et al.  Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors , 2014, Genome Medicine.

[13]  Annette Lee,et al.  Genome-Wide Methylation Analyses in Glioblastoma Multiforme , 2014, PloS one.

[14]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[15]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[16]  Charlotte Soneson,et al.  A glioma classification scheme based on coexpression modules of EGFR and PDGFRA , 2014, Proceedings of the National Academy of Sciences.

[17]  Jin-xiang Cheng,et al.  TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway , 2014, Oncogene.

[18]  Jin-xiang Cheng,et al.  The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis , 2014, PloS one.

[19]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[20]  Jin-xiang Cheng,et al.  Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis , 2013, PloS one.

[21]  Francesco Marabita,et al.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data , 2012, Bioinform..

[22]  M. Preusser,et al.  Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how? , 2012, Clinical neuropathology.

[23]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[24]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[25]  M. Delorenzi,et al.  MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.

[26]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[27]  J. Issa.  DNA methylation as a clinical marker in oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  O. Ammerpohl,et al.  Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina, Inc. , 2012, BMC Research Notes.

[29]  A. Italiano,et al.  Prognostic or predictive? It's time to get back to definitions! , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Boris Freidlin,et al.  Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Sidransky,et al.  Promoter methylation of heat shock protein B2 in human esophageal squamous cell carcinoma. , 2011, International journal of oncology.

[32]  J. Mosser,et al.  DNA methylation in glioblastoma: impact on gene expression and clinical outcome , 2010, BMC Genomics.

[33]  Xiao Zhang,et al.  Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis , 2010, BMC Bioinformatics.

[34]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[35]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[37]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[38]  Paul S Rennie,et al.  Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells , 2007, Molecular Cancer.

[39]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[40]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[41]  Xin Yu,et al.  Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. , 2002, The American journal of pathology.

[42]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[43]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Arul M Chinnaiyan,et al.  Translating cancer genomes and transcriptomes for precision oncology , 2016, CA: a cancer journal for clinicians.

[45]  Jingde Zhu,et al.  Use of DNA methylation for cancer detection: promises and challenges. , 2009, The international journal of biochemistry & cell biology.

[46]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.